SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: seminole who wrote (1007)5/20/1998 2:37:00 PM
From: David Cathcart  Read Replies (1) of 1826
 
Richard,

Perhaps the company should have stated the efficacy signs from early on in the phase I trial. The two signs of efficacy strike me as insignificant though and introduce questions of their own. If the drug worked in low doses, why did it not work at doses that were two or three fold higher? Why did it only work in 2 out of at least 28 patients? So, while the efficacy cases could have been mentioned, I question whether they would have helped or hurt the story at this point. What matters in phase I is reaching a reasonable dose level. What matters in phase II is efficacy. We've got the dose level, let's now dose some tumors that are small and sparse enough to be effected.

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News